Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:SRDX's Cash-to-Debt is ranked higher than
96% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. NAS:SRDX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SRDX' s Cash-to-Debt Range Over the Past 10 Years
Min: 50.6  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.83
NAS:SRDX's Equity-to-Asset is ranked higher than
82% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NAS:SRDX: 0.83 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SRDX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.74  Med: 0.92 Max: 0.96
Current: 0.83
0.74
0.96
Interest Coverage No Debt
NAS:SRDX's Interest Coverage is ranked higher than
96% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. NAS:SRDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:SRDX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 10.79
Beneish M-Score: -2.83
WACC vs ROIC
6.37%
14.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 21.29
NAS:SRDX's Operating Margin % is ranked higher than
91% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. NAS:SRDX: 21.29 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SRDX' s Operating Margin % Range Over the Past 10 Years
Min: -20.11  Med: 30.13 Max: 47.31
Current: 21.29
-20.11
47.31
Net Margin % 12.88
NAS:SRDX's Net Margin % is ranked higher than
88% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. NAS:SRDX: 12.88 )
Ranked among companies with meaningful Net Margin % only.
NAS:SRDX' s Net Margin % Range Over the Past 10 Years
Min: -35.08  Med: 17.25 Max: 30.9
Current: 12.88
-35.08
30.9
ROE % 9.00
NAS:SRDX's ROE % is ranked higher than
64% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. NAS:SRDX: 9.00 )
Ranked among companies with meaningful ROE % only.
NAS:SRDX' s ROE % Range Over the Past 10 Years
Min: -12.91  Med: 10.43 Max: 23.9
Current: 9
-12.91
23.9
ROA % 7.36
NAS:SRDX's ROA % is ranked higher than
79% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. NAS:SRDX: 7.36 )
Ranked among companies with meaningful ROA % only.
NAS:SRDX' s ROA % Range Over the Past 10 Years
Min: -11.85  Med: 8.38 Max: 19.94
Current: 7.36
-11.85
19.94
ROC (Joel Greenblatt) % 70.96
NAS:SRDX's ROC (Joel Greenblatt) % is ranked higher than
90% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. NAS:SRDX: 70.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SRDX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -18.72  Med: 85.11 Max: 110.87
Current: 70.96
-18.72
110.87
3-Year Revenue Growth Rate 12.30
NAS:SRDX's 3-Year Revenue Growth Rate is ranked higher than
73% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NAS:SRDX: 12.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SRDX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -24.6  Med: 15.45 Max: 57.9
Current: 12.3
-24.6
57.9
3-Year EBITDA Growth Rate 3.70
NAS:SRDX's 3-Year EBITDA Growth Rate is ranked higher than
51% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. NAS:SRDX: 3.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SRDX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -32.7  Med: 14.05 Max: 90.6
Current: 3.7
-32.7
90.6
3-Year EPS without NRI Growth Rate -8.40
NAS:SRDX's 3-Year EPS without NRI Growth Rate is ranked lower than
60% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. NAS:SRDX: -8.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SRDX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -35.4  Med: 11.8 Max: 48.3
Current: -8.4
-35.4
48.3
GuruFocus has detected 3 Warning Signs with Surmodics Inc $NAS:SRDX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SRDX's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

SRDX Guru Trades in Q2 2016

Jim Simons 850,538 sh (+2.21%)
Mario Gabelli 107,548 sh (unchged)
Chuck Royce 502,600 sh (-12.83%)
Paul Tudor Jones 12,206 sh (-16.17%)
Mairs and Power 11,700 sh (-29.94%)
» More
Q3 2016

SRDX Guru Trades in Q3 2016

Jim Simons 860,138 sh (+1.13%)
Mario Gabelli 106,048 sh (-1.39%)
Mairs and Power 10,338 sh (-11.64%)
Paul Tudor Jones 9,647 sh (-20.97%)
Chuck Royce 328,092 sh (-34.72%)
» More
Q4 2016

SRDX Guru Trades in Q4 2016

Jim Simons 964,038 sh (+12.08%)
Chuck Royce 328,092 sh (unchged)
Mairs and Power Sold Out
Mario Gabelli 105,648 sh (-0.38%)
Paul Tudor Jones 8,878 sh (-7.97%)
» More
Q1 2017

SRDX Guru Trades in Q1 2017

Chuck Royce 368,092 sh (+12.19%)
Jim Simons 1,002,721 sh (+4.01%)
Mario Gabelli 105,648 sh (unchged)
Paul Tudor Jones 8,502 sh (-4.24%)
» More
» Details

Insider Trades

Latest Guru Trades with SRDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:NAS:ONVO, NAS:QTNT, NAS:OXFD, NAS:RDNT, NAS:MGEN, NAS:PACB, NYSE:NVTA, NAS:NVDQ, NYSE:ENZ, OTCPK:EPGNF, NAS:FLDM, OTCPK:CBIS, NAS:AIQ, AMEX:SENS, NAS:TRIB, NAS:FLGT, NAS:PMD, NAS:CTSO, NAS:VRML, NAS:TTOO » details
Traded in other countries:SU6.Germany,
Headquarter Location:USA
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry.

Surmodics Inc was organized as a Minnesota corporation in June 1979. The Company is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. Its business units are organized and managed in two reportable segments, Medical Device and In Vitro Diagnostics. The core offerings in its Medical Device business unit include surface modification coating technologies that impart lubricity, prohealing or biocompatibility characteristics, or drug delivery capabilities. It manufactures or sells components for in vitro diagnostic immunoassay and molecular tests and it manufactures and sells surface coatings to the diagnostic, biomedical research, and life science markets. The In Vitro Diagnostics products include Protein Stabilizers, Substrates, Recombinant Human Antigens, and Surface Coatings for Molecular Diagnostic Applications.

Ratios

vs
industry
vs
history
PE Ratio 31.94
SRDX's PE Ratio is ranked lower than
52% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. SRDX: 31.94 )
Ranked among companies with meaningful PE Ratio only.
SRDX' s PE Ratio Range Over the Past 10 Years
Min: 8.52  Med: 29.34 Max: 584.75
Current: 31.94
8.52
584.75
Forward PE Ratio 109.89
SRDX's Forward PE Ratio is ranked lower than
96% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. SRDX: 109.89 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 31.94
SRDX's PE Ratio without NRI is ranked lower than
51% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. SRDX: 31.94 )
Ranked among companies with meaningful PE Ratio without NRI only.
SRDX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.52  Med: 28.94 Max: 584.75
Current: 31.94
8.52
584.75
Price-to-Owner-Earnings 23.13
SRDX's Price-to-Owner-Earnings is ranked higher than
55% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. SRDX: 23.13 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SRDX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.81  Med: 34.95 Max: 289.07
Current: 23.13
13.81
289.07
PB Ratio 2.76
SRDX's PB Ratio is ranked higher than
59% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. SRDX: 2.76 )
Ranked among companies with meaningful PB Ratio only.
SRDX' s PB Ratio Range Over the Past 10 Years
Min: 0.98  Med: 3.04 Max: 7.42
Current: 2.76
0.98
7.42
PS Ratio 4.12
SRDX's PS Ratio is ranked lower than
58% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. SRDX: 4.12 )
Ranked among companies with meaningful PS Ratio only.
SRDX' s PS Ratio Range Over the Past 10 Years
Min: 2.17  Med: 5.2 Max: 13.77
Current: 4.12
2.17
13.77
Price-to-Free-Cash-Flow 30.85
SRDX's Price-to-Free-Cash-Flow is ranked lower than
59% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. SRDX: 30.85 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SRDX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.26  Med: 20.82 Max: 503.11
Current: 30.85
7.26
503.11
Price-to-Operating-Cash-Flow 15.21
SRDX's Price-to-Operating-Cash-Flow is ranked higher than
60% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. SRDX: 15.21 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SRDX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.99  Med: 16.03 Max: 30.15
Current: 15.21
5.99
30.15
EV-to-EBIT 16.29
SRDX's EV-to-EBIT is ranked higher than
69% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. SRDX: 16.29 )
Ranked among companies with meaningful EV-to-EBIT only.
SRDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.7  Med: 15.6 Max: 103.8
Current: 16.29
-37.7
103.8
EV-to-EBITDA 12.24
SRDX's EV-to-EBITDA is ranked higher than
70% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. SRDX: 12.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
SRDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -167.5  Med: 13.1 Max: 66.8
Current: 12.24
-167.5
66.8
PEG Ratio 3.14
SRDX's PEG Ratio is ranked lower than
56% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. SRDX: 3.14 )
Ranked among companies with meaningful PEG Ratio only.
SRDX' s PEG Ratio Range Over the Past 10 Years
Min: 1.32  Med: 3.24 Max: 3.93
Current: 3.14
1.32
3.93
Shiller PE Ratio 46.72
SRDX's Shiller PE Ratio is ranked lower than
67% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. SRDX: 46.72 )
Ranked among companies with meaningful Shiller PE Ratio only.
SRDX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.08  Med: 43.09 Max: 132.12
Current: 46.72
17.08
132.12
Current Ratio 8.66
SRDX's Current Ratio is ranked higher than
91% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. SRDX: 8.66 )
Ranked among companies with meaningful Current Ratio only.
SRDX' s Current Ratio Range Over the Past 10 Years
Min: 1.57  Med: 5.92 Max: 18.27
Current: 8.66
1.57
18.27
Quick Ratio 8.17
SRDX's Quick Ratio is ranked higher than
91% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. SRDX: 8.17 )
Ranked among companies with meaningful Quick Ratio only.
SRDX' s Quick Ratio Range Over the Past 10 Years
Min: 1.49  Med: 5.43 Max: 18
Current: 8.17
1.49
18
Days Inventory 115.37
SRDX's Days Inventory is ranked lower than
61% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. SRDX: 115.37 )
Ranked among companies with meaningful Days Inventory only.
SRDX' s Days Inventory Range Over the Past 10 Years
Min: 33.96  Med: 123.11 Max: 168.39
Current: 115.37
33.96
168.39
Days Sales Outstanding 34.92
SRDX's Days Sales Outstanding is ranked higher than
86% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. SRDX: 34.92 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.19  Med: 35.38 Max: 80.51
Current: 34.92
30.19
80.51
Days Payable 61.64
SRDX's Days Payable is ranked lower than
51% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. SRDX: 61.64 )
Ranked among companies with meaningful Days Payable only.
SRDX' s Days Payable Range Over the Past 10 Years
Min: 33.07  Med: 57.73 Max: 166.09
Current: 61.64
33.07
166.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.70
SRDX's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. SRDX: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SRDX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.1  Med: 0.9 Max: 8.1
Current: 1.7
-5.1
8.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 12.38
SRDX's Price-to-Net-Cash is ranked lower than
57% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.15 vs. SRDX: 12.38 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SRDX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.9  Med: 24.21 Max: 700
Current: 12.38
3.9
700
Price-to-Net-Current-Asset-Value 8.28
SRDX's Price-to-Net-Current-Asset-Value is ranked lower than
52% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. SRDX: 8.28 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SRDX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.27  Med: 16.07 Max: 160.14
Current: 8.28
3.27
160.14
Price-to-Tangible-Book 4.85
SRDX's Price-to-Tangible-Book is ranked higher than
50% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. SRDX: 4.85 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SRDX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.26  Med: 4.61 Max: 18.49
Current: 4.85
1.26
18.49
Price-to-Intrinsic-Value-Projected-FCF 1.01
SRDX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
86% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. SRDX: 1.01 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SRDX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.42 Max: 6.54
Current: 1.01
0.52
6.54
Price-to-Median-PS-Value 0.80
SRDX's Price-to-Median-PS-Value is ranked higher than
68% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. SRDX: 0.80 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SRDX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 1.59 Max: 9.22
Current: 0.8
0.48
9.22
Price-to-Peter-Lynch-Fair-Value 3.54
SRDX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
67% of the 27 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. SRDX: 3.54 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
SRDX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.47  Med: 1.83 Max: 31.8
Current: 3.54
0.47
31.8
Price-to-Graham-Number 2.63
SRDX's Price-to-Graham-Number is ranked higher than
56% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.97 vs. SRDX: 2.63 )
Ranked among companies with meaningful Price-to-Graham-Number only.
SRDX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.91  Med: 2.79 Max: 13.55
Current: 2.63
0.91
13.55
Earnings Yield (Greenblatt) % 6.14
SRDX's Earnings Yield (Greenblatt) % is ranked higher than
81% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. SRDX: 6.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SRDX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1  Med: 6.1 Max: 22
Current: 6.14
1
22
Forward Rate of Return (Yacktman) % 13.79
SRDX's Forward Rate of Return (Yacktman) % is ranked higher than
75% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. SRDX: 13.79 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
SRDX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.9  Med: 4.75 Max: 36.4
Current: 13.79
1.9
36.4

More Statistics

Revenue (TTM) (Mil) $73.39
EPS (TTM) $ 0.71
Beta0.69
Short Percentage of Float3.88%
52-Week Range $21.56 - 30.75
Shares Outstanding (Mil)13.28

Analyst Estimate

Sep17 Sep18 Sep19
Revenue (Mil $) 68 71 76
EPS ($) 0.21 0.26 0.32
EPS without NRI ($) 0.21 0.26 0.32
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.00%
Dividends per Share ($)
» More Articles for SRDX

Headlines

Articles On GuruFocus.com
5 Best Stocks for Value Investors This Week Feb 19 2017 
SurModics Inc. Reports Operating Results (10-Q) Aug 06 2010 
SurModics Inc. Reports Operating Results (10-Q) May 07 2010 
SurModics Inc. Reports Operating Results (10-Q) Feb 05 2010 
SurModics Inc. Reports Operating Results (10-K) Dec 11 2009 
SurModics Inc. (SRDX) Senior VP & CFO Philip D Ankeny sells 5,000 Shares Oct 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Aug 07 2009 
SurModics Inc. Reports Operating Results (10-Q) May 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
Surmodics to Present at Upcoming Investor Conferences May 22 2017
ETFs with exposure to SurModics, Inc. : May 5, 2017 May 05 2017
SurModics, Inc. :SRDX-US: Earnings Analysis: Q2, 2017 By the Numbers : May 3, 2017 May 03 2017
Edited Transcript of SRDX earnings conference call or presentation 27-Apr-17 12:30pm GMT May 01 2017
SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : April 28, 2017 Apr 28 2017
SurModics posts 2Q profit Apr 27 2017
Surmodics Reports Second Quarter Fiscal 2017 Results, Updates Fiscal 2017 Financial Guidance Apr 27 2017
SurModics, Inc. – Value Analysis (NASDAQ:SRDX) : April 19, 2017 Apr 19 2017
SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : April 18, 2017 Apr 18 2017
Surmodics to Webcast Second Quarter 2017 Earnings Conference Call on April 27 Apr 18 2017
Surmodics Appoints Lisa Wipperman Heine to Its Board of Directors Apr 17 2017
SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : March 20, 2017 Mar 20 2017
Surmodics to Present at Oppenheimer Healthcare Conference Mar 14 2017
Why Is Surmodics (SRDX) Down 2.7% Since the Last Earnings Report? Mar 08 2017
SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : March 6, 2017 Mar 06 2017
SurModics, Inc. :SRDX-US: Earnings Analysis: Q1, 2017 By the Numbers : February 15, 2017 Feb 15 2017
Surmodics Announces 2017 Annual Shareholders Meeting Feb 09 2017
SurModics (SRDX) Beats Earnings & Revenue Estimates in Q1 Feb 06 2017
Edited Transcript of SRDX earnings conference call or presentation 2-Feb-17 1:30pm GMT Feb 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat